| NOVOCURE LTD |
| Großbritannien |
| Gesundheit |
| JE00BYSS4X48 / A140ML |
| 038 (Frankfurt) / NVCR (NASDAQ) |
| FRA:038, ETR:038, 038:GR, NASDAQ:NVCR |
| - |
| https://www.novocure.com/ |
|
Novocure Ltd. is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), an innovative, non-invasive cancer therapy using alternating electric fields tuned to specific frequencies to disrupt cancer cell division w..
>Volltext.. |
| 1068.63 Mio. EUR |
| 890.62 Mio. EUR |
| 567.74 Mio. EUR |
| -120.55 Mio. EUR |
| -118.02 Mio. EUR |
| -1.06 EUR |
| 215.15 Mio. EUR |
| 89.57 Mio. EUR |
| -42.48 Mio. EUR |
| 2.05 |
| -4.56% |
| 28.79% |
| - |
| - |
| - |
| NOVOCURE |
| 04.04.26 |
|